<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mendelian susceptibility to mycobacterial diseases: An overview</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mendelian susceptibility to mycobacterial diseases: An overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Mendelian susceptibility to mycobacterial diseases: An overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alexandra F Freeman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven M Holland, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer M Puck, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 01, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H26818138"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The conditions grouped together under Mendelian susceptibility to mycobacterial diseases (MSMD; MIM #209950) are caused by genetic defects affecting the interactions of mononuclear phagocytes and T helper cells around the synthesis and response to interferon (IFN) gamma, often referred to as the T helper cell type 1 (Th1) pathway [<a href="#rid1">1</a>]. These diseases were recognized through severe adverse effects related to the administration of Bacillus Calmette-Guérin (BCG), the live-attenuated tuberculosis vaccine, in the first days of life. In countries in which BCG is not given, the clinical and infectious manifestations of MSMD may differ, as infections are dominated by environmental mycobacteria but also dimorphic yeasts and bacteria. In addition, anticytokine autoantibodies that block IFN-gamma, the critical mediator of this pathway, mimic the genetic disorders and should be considered in the differential for MSMD.</p><p>Infectious agents in patients with MSMD tend to be weakly virulent environmental organisms including mycobacteria (the nontuberculous mycobacteria [NTM], BCG, occasionally <em>Mycobacterium tuberculosis</em>); bacteria (salmonellae, some <em>Burkholderia</em>, <em>Listeria</em>); fungi, especially the dimorphic molds (<em>Histoplasma</em>, <em>Blastomyces</em>, <em>Coccidioides</em>, cryptococci); and the intracellular parasite <em>Leishmania</em>. In addition, herpes virus family infections are more common and can be severe, including herpes simplex virus (HSV) type 1 and 2, cytomegalovirus (CMV), and Epstein-Barr virus (EBV), which can cause EBV+ neoplasms  (<a class="graphic graphic_table graphicRef129034" href="/z/d/graphic/129034.html" rel="external">table 1</a>). Thus, while the name of this group of diseases was coined from susceptibility to mycobacterial infections, these conditions really involve susceptibility to the broader group of intracellular infections of macrophages, including bacteria, fungi, and viruses.</p><p>This topic reviews the pathogenesis, typical presentation, diagnosis, and general management. Specific diseases are reviewed separated. (See  <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: Specific defects"</a>.)</p><p class="headingAnchor" id="H3197179550"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>The ability of macrophages to kill intracellular pathogens depends heavily upon the functional integrity of their interaction with T cells, which is mediated by both cell surface markers and soluble cytokines. Interferon (IFN) gamma is a pleiotropic cytokine, produced predominantly by T helper cell type 1 (Th1) cells, that is essential for elimination of the numerous infectious organisms (bacterial, parasitic, and mycobacterial) that target and reside in the intracellular niche [<a href="#rid2">2-8</a>]. This same set of pathways is also critical in the control of certain viral infections, especially those of the herpes family. (See  <a class="medical medical_review" href="/z/d/html/5345.html" rel="external">"Pathogenesis of nontuberculous mycobacterial infections"</a>.)</p><p>When macrophages are infected with mycobacteria or other intracellular pathogens, they produce the cytokines interleukin (IL) 12 (a heterodimer of IL-12 p40 plus IL-12 p35) [<a href="#rid9">9</a>], which stimulates T cells and natural killer (NK) cells via its cell surface heterodimeric receptor (IL-12Rb1 plus IL-12Rb2) and IL-23 (a heterodimer of IL-12 p40 plus IL-23 p19). In response to stimulation with IL-12 and IL-23, activated T cells and NK cells produce IFN-gamma  (<a class="graphic graphic_figure graphicRef50107" href="/z/d/graphic/50107.html" rel="external">figure 1</a>). IFN-gamma binds to its cell surface heterodimeric receptor (IFNGR1 and IFNGR2), leading to receptor dimerization. The Janus kinases, JAK1 and JAK2, are tyrosine kinases constitutively associated with the intracellular IFNGR1 and IFNGR2 chains, respectively. With receptor occupation, JAK1 and JAK2 transphosphorylate each other, leading to phosphorylation of the intracellular portion of IFNGR1. This phosphorylated site recruits and facilitates the phosphorylation of signal transducer and activator of transcription (STAT) 1, making pSTAT1. pSTAT1 homodimerizes and then translocates to the nucleus, where it binds to promoters of IFN-gamma-regulated genes  (<a class="graphic graphic_figure graphicRef91737" href="/z/d/graphic/91737.html" rel="external">figure 2</a>) [<a href="#rid10">10,11</a>].</p><p>IFN-gamma activation leads to the production of tumor necrosis factor (TNF) alpha, further upregulation of IL-12 production, and production of superoxide through the NADPH oxidase, among other properties. The specific effector mechanism by which IFN-gamma promotes mycobacterial killing remains unknown. (See  <a class="medical medical_review" href="/z/d/html/3925.html" rel="external">"Chronic granulomatous disease: Pathogenesis, clinical manifestations, and diagnosis", section on 'Activation of NADPH oxidase'</a>.)</p><p>Many genes are impacted by the IL-12/IFN-gamma pathway and regulate it in turn. MSMD typically refers to defects in <em>IFNGR1</em>, <em>IFNGR2</em>, IL-12 receptor beta 1 (<em>IL12RB1</em>), IL-12 receptor beta 2 (<em>IL12RB2</em>), IL-12 p40 (<em>IL12B</em>), <em>STAT1</em>, tyrosine kinase 2 (<em>TYK2</em>)<em>,</em> IFN regulatory factor 8 (<em>IRF8</em>), the zinc-finger transcription factor GATA2 (<em>GATA2</em>), IFN-stimulated gene 15 (<em>ISG15</em>), <em>IKBKG</em> (which encodes the NFKB essential modulator [NEMO]), <em>NFKBIA</em>, RORgamma/RORgammaT (<em>RORC</em>), and signal peptide peptidase-like 2A (<em>SPPL2A</em>) [<a href="#rid12">12</a>]. Each specific defect is discussed in detail separately. The genetic defect is unidentified in approximately half of patients with disseminated nontuberculous mycobacterial (NTM) disease. Anticytokine autoantibodies to IFN-gamma account for some of the cases in which MSMD defects are not found. (See  <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: Specific defects"</a>.)</p><p class="headingAnchor" id="H26818150"><span class="h1">PRESENTATION AND CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Patients with MSMD typically present with severe Bacillus Calmette-Guérin (BCG; a live-attenuated strain of <em>Mycobacterium bovis</em> used in a vaccine to prevent tuberculosis and other mycobacterial infections), environmental nontuberculous mycobacterial (NTM), or other infections  (<a class="graphic graphic_table graphicRef129034" href="/z/d/graphic/129034.html" rel="external">table 1</a>) [<a href="#rid13">13</a>]. As BCG vaccination is given in the first days of life, patients tend to present in early childhood, weeks to months after vaccination, but the times can vary.</p><p>Clinical features of disseminated NTM infection are nonspecific and may include fever, weight loss, diarrhea, generalized lymphadenopathy, generalized cutaneous lesions, diffuse abdominal tenderness, hepatosplenomegaly, and ascites. Symptoms and signs reflect the major sites of involvement (eg, bone marrow, lymphoreticular system, gastrointestinal tract, lungs). Partial defects, such as that caused by the autosomal-dominant (AD) partial interferon (IFN) gamma receptor 1 (ADIFNGR1) deficiency, often present with more limited disease such as NTM osteomyelitis and often later in childhood or even adulthood. Skin lesions are common in patients with disseminated infection. The clinical manifestations of disseminated disease are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/14425.html" rel="external">"Disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children", section on 'Clinical features'</a>.)</p><p>Most cases of disseminated BCG infection present within weeks to months of immunization. Clinical manifestations are similar to those for environmental NTM infection, with a few exceptions. The lymph nodes draining the site of inoculation may fistulize to skin and surrounding tissues. Diffuse disseminated disease with extensive liver, gut, and bloodstream involvement; meningitis; brain abscesses; and osteomyelitis may occur. (See  <a class="medical medical_review" href="/z/d/html/8022.html" rel="external">"Prevention of tuberculosis: BCG immunization and nutritional supplementation", section on 'Safety and adverse effects'</a>.)</p><p>The mode of presentation and the particular mycobacterial strain depend upon geographic location and whether <a class="drug drug_general" data-topicid="102736" href="/z/d/drug information/102736.html" rel="external">BCG vaccine</a> was administered [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In countries that administer <a class="drug drug_general" data-topicid="102736" href="/z/d/drug information/102736.html" rel="external">BCG vaccine</a>, the clinical presentation is usually infection with the vaccine strain. Many labs have difficulty distinguishing BCG from tuberculosis (TB) in routine testing, so the diagnosis of disseminated TB in an infant or child who was BCG vaccinated should always include MSMD in the differential.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In countries where the first encounter with mycobacteria is via environmental exposure, infection with a wide variety of NTM occurs, such as <em>Mycobacterium avium </em>complex, <em>Mycobacterium fortuitum</em>, <em>Mycobacterium chelonae</em>, or <em>Mycobacterium kansasii</em>.</p><p></p><p>Disease severity and age of onset depend upon the part of the IFN-gamma pathway affected and the degree of the genetic defect (partial or complete)  (<a class="graphic graphic_table graphicRef140002" href="/z/d/graphic/140002.html" rel="external">table 2</a>). Patients with complete defects typically present in early childhood with disseminated disease [<a href="#rid14">14</a>], whereas those with partial or less severe defects in <em>IFNGR1</em>, <em>IRF8</em>, or <em>IL12RB1</em> may present in adolescence or adulthood with milder recurrent infections. Patients who live in highly <em>M. tuberculosis</em> (TB) endemic parts of the world may present with disseminated TB [<a href="#rid1">1</a>]. MSMD defects rarely if ever present as isolated or recurrent lung disease, especially in adulthood.</p><p>Certain clinical features suggest particular defects. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>NTM osteomyelitis in patients with AD partial IFN-gamma receptor deficiencies (see  <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: Specific defects", section on 'Autosomal dominant partial IFNGR1 deficiency'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increased susceptibility to severe viral infections, including cytomegalovirus (CMV), respiratory syncytial virus (RSV), varicella-zoster virus (VZV), and parainfluenza virus, in patients with autosomal-recessive (AR) signal transducer and activator of transcription 1 (STAT1) deficiency (see  <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: Specific defects", section on 'STAT1 defects'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mucocutaneous candidiasis in patients with <em>STAT1</em> gain-of-function (GOF) pathogenic variants, interleukin 12 receptor beta 1 (IL12RB1) deficiency, and those with AD <em>NFKBIA</em> mutations (see  <a class="medical medical_review" href="/z/d/html/13569.html" rel="external">"Chronic mucocutaneous candidiasis", section on 'Signal transducer and activator of transcription (STAT1) dysfunction'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infection with dimorphic fungi in patients with <em>STAT1</em> GOF pathogenic variants, IFN-gamma receptor deficiencies, and IL-12RB1 deficiency</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ectodermal dysplasia, as well as inflammatory bowel disease, with <em>IKBKG</em> and <em>NFKBIA</em> pathogenic variants</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Absolute circulating monocytopenia, natural killer (NK) cell cytopenia, B cell lymphopenia, myelodysplasia, myeloid malignancies, pulmonary alveolar proteinosis, or disseminated warts in patients with GATA2 deficiency (see  <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: Specific defects", section on 'GATA2 deficiency (MonoMAC syndrome)'</a>)</p><p></p><p class="headingAnchor" id="H26818156"><span class="h1">GENERAL APPROACH TO DIAGNOSIS</span><span class="headingEndMark"> — </span>An underlying genetic cause should be sought in all children and adults with recurrent or disseminated nontuberculous mycobacterial (NTM) infection or disseminated Bacillus Calmette-Guérin (BCG) infection. The more common pediatric condition of isolated cervical or thoracic NTM lymphadenopathy has not been genetically characterized, although rarely these cases have had autosomal-dominant (AD) partial interferon (IFN) gamma receptor 1 deficiency (ADIFNGR1). Young children presenting with isolated cervical NTM adenitis are typically not screened for MSMD unless the infections are difficult to treat or recur. For those with disseminated disease, proper treatment of MSMD hinges upon identification of the underlying molecular defect, the specific organism causing the infection, and the extent of disease [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H3716682343"><span class="h2">Identification of the pathogenic mycobacteria</span><span class="headingEndMark"> — </span>Definitive determination of the specific infecting mycobacteria is important for choosing treatment and for determining epidemiology. There are over 150 different mycobacterial species. Methods currently in use include culture, direct molecular identification, and proteomic detection. In disseminated disease, NTM frequently can be grown from mycobacterial blood cultures (these need to be ordered separately from routine blood cultures). For more isolated disease, such as NTM osteomyelitis, culture of the infected tissue is typically required to make the diagnosis. If histopathology demonstrates acid-fast bacilli (AFB) and mycobacterial cultures are not performed or are negative, then direct polymerase chain reaction (PCR) on tissue samples may allow determination of the NTM species. When the suspicion differential is between BCG and <em>M. tuberculosis</em>, molecular typing is required to distinguish them<em> </em>[<a href="#rid16">16</a>]. Molecular drug-resistance testing can be done molecularly, but antibiotic susceptibility testing still requires growth in culture. Diagnostic testing for NTM infection is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5343.html" rel="external">"Microbiology of nontuberculous mycobacteria"</a> and  <a class="medical medical_review" href="/z/d/html/14425.html" rel="external">"Disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/86045.html" rel="external">"Nontuberculous mycobacterial lymphadenitis in children", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/85895.html" rel="external">"Nontuberculous mycobacterial skin and soft tissue infections in children", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H4026884094"><span class="h2">Immunologic testing</span><span class="headingEndMark"> — </span>Cytokine secretion and response and cell-surface or intracellular molecule detection by flow cytometry have been used as research tests but suffer from poor standardization and difficulty in transporting live cells to specialty labs for testing. In addition, functional tests to interrogate pathways are not definitive, and no functional tests are available to exclude all forms of MSMD [<a href="#rid17">17</a>]. Since the purpose of the functional tests is to guide the exploration of defects in specific genes, it is now easier, faster, more reliable, and much less expensive to move right to molecular testing (gene panels or whole exome or genome; in the case of panels, it is imperative to know which genes are included) (see <a class="local">'Identification of the molecular defect'</a> below). With molecular tests in hand, there will still be variants of uncertain significance (VUS) that will need functional confirmation, which can be done with commercial or research labs, but will be focused on select pathways. The findings expected for each known defect are shown in the table  (<a class="graphic graphic_table graphicRef140002" href="/z/d/graphic/140002.html" rel="external">table 2</a>). Surface expression of IFNGR1 (CD119) can be determined by flow cytometry, but it not widely available. Absence suggests recessive IFNGR1 deficiency, while excess IFNGR1 display on the cell surface suggests the dominant partial form of deficiency, ADIFNGR1. (See  <a class="medical medical_review" href="/z/d/html/3937.html" rel="external">"Flow cytometry for the diagnosis of inborn errors of immunity"</a>.)</p><p class="headingAnchor" id="H879440632"><span class="h2">Identification of the molecular defect</span><span class="headingEndMark"> — </span>Genetic testing is the only definitive way to identify genetic diseases, and the molecular diagnosis affects treatment decisions, such as IFN-gamma therapy or hematopoietic cell transplantation (HCT), and prognosis [<a href="#rid18">18</a>]. Candidate genes can be screened individually in panels by whole-exome sequencing (WES) or by whole-genome sequencing (WGS). Particular attention is necessary when a defect in the <em>IKBKG </em>gene is suspected, as the <em>IKBKG</em> gene encoding NEMO has pseudogenes that make genomic sequencing difficult to interpret. Thus, sequencing of complementary DNA (cDNA), derived from spliced <em>IKBKG</em> mRNA, is required to make a reliable diagnosis of IKBKG mutation. GATA-binding protein 2 (GATA2) deficiency can be caused by intronic pathogenic variants that are missed on WES. (See  <a class="medical medical_review" href="/z/d/html/3903.html" rel="external">"Laboratory evaluation of the immune system", section on 'Advanced genomic studies for all forms of IEIs'</a>.)</p><p>The purified protein derivative [PPD] test and the IFN-gamma release assay (IGRA; diagnostic tests for <em>M. tuberculosis</em> infection) may be difficult in patients with MSMD. In general, NTM do not provoke a positive IGRA, which depends on the antigens ESAT6 and CFP10 in <em>M. tuberculosis</em> but not in BCG (note that <em>M. kansasii, M. marinum</em> and M<em>. szulgai</em> can also give positive IGRA assay results). Defects in the IFN-gamma/interleukin (IL) 12 pathway may give variable results depending on the specific organism and the specific defect. It is important to be aware that anti-IFN-gamma autoantibodies cause an indeterminate IGRA since the antibody blocks detection of IFN-gamma in the positive control tube [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H26818174"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis in patients with disseminated nontuberculous mycobacterial (NTM) or BCG infections includes the following:</p><p class="bulletIndent1"><span class="glyph">●</span>T cell immunodeficiencies, such as severe combined immunodeficiency (SCID) or combined immunodeficiency syndromes are particularly associated with disseminated BCG infections but much less with NTM. Patients with SCID typically have very low naïve T cells and impaired proliferative responses to mitogens such as phytohemagglutinin (PHA), typically present in early infancy, and have a broad susceptibility to infection. These children should be identified on newborn T cell receptor excision circle (TREC) screening. (See  <a class="medical medical_review" href="/z/d/html/3955.html" rel="external">"Severe combined immunodeficiency (SCID): An overview", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/16363.html" rel="external">"Newborn screening for inborn errors of immunity", section on 'Screening for SCID and other T cell defects'</a> and  <a class="medical medical_review" href="/z/d/html/3935.html" rel="external">"Combined immunodeficiencies: An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hairy cell leukemia has a high incidence of disseminated NTM, much more than other lymphoid malignancies. This disease has an adult onset, distinct from MSMD defects. (See  <a class="medical medical_review" href="/z/d/html/4532.html" rel="external">"Clinical features and diagnosis of hairy cell leukemia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autoantibodies to interferon (IFN) gamma cause disseminated NTM infections. Most reported patients are from Southeast Asia and have adult-onset disease [<a href="#rid20">20-24</a>]. Some patients with these autoantibodies to IFN-gamma present with other opportunistic infections (eg, <em>Cryptococcus neoformans</em>, <em>Histoplasma capsulatum</em>, and <em>Talaromyces </em>[<em>Penicillium</em>]<em> marneffei</em>), salmonellosis, or severe varicella-zoster virus (VZV) infection, with or without NTM infections [<a href="#rid22">22</a>]. No familial clustering has been reported. In patients with late-onset disseminated mycobacterial infection, anti-IFN-gamma antibodies with neutralizing activity should be sought. Options for treatment in these patients include targeted anti-B cell therapy [<a href="#rid25">25,26</a>]. These patients will invariably have an indeterminate IFN-gamma release assay due to the presence of neutralizing anti-IFN-gamma autoantibodies, which block the signal in the positive control tube [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary immunodeficiency due to immune-suppressing medications. Tumor necrosis factor (TNF) alpha blockers, Janus kinase (JAK) inhibitors, and interleukin (IL) 12/23 blockers increase susceptibility to mycobacterial infection [<a href="#rid27">27,28</a>].</p><p></p><p class="headingAnchor" id="H26818180"><span class="h1">GENERAL APPROACH TO TREATMENT</span><span class="headingEndMark"> — </span>Aggressive treatment with antimycobacterial antibiotics remains the most important management for patients with these disorders [<a href="#rid29">29,30</a>]. Cytokine replacement therapy with interferon (IFN) gamma is an additional treatment option in patients with defects that preserve the IFN-gamma receptor, but it should be used with expert consultation.</p><p>The antibiotics used for NTM infections in patients with MSMD are the same as those used for other patients, but treatment intensity and duration in patients with MSMD are greater since the burden of disease is typically higher and the immune contribution is lower [<a href="#rid31">31</a>]. The duration of treatment is based upon clinical response, radiologic improvement, and microbiologic cure. Patients should be maintained on secondary antibiotic prophylaxis once the infection is successfully cleared, typically with daily <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>. Treatment of NTM infections is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/14425.html" rel="external">"Disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children"</a>.)</p><p>Most MSMD, other than complete IFN-gamma receptor defects and complete (autosomal-recessive [AR]) signal transducer and activator of transcription 1 (STAT1) defects, are responsive, at least to some degree, to IFN-gamma therapy [<a href="#rid1">1</a>]. IFN-gamma therapy is typically added for defects with residual response to IFN-gamma therapy (such as autosomal-dominant [AD] partial IFN-gamma receptor 1 [ADIFNGR1] deficiency) when response to antibiotic management is unsuccessful at clearing or ameliorating infection after several months of adherent therapy. Patients with interleukin (IL) 12 receptor beta 1 (IL-12RB1) defects may respond to IFN-gamma therapy but may develop hyperinflammation, such as a hemophagocytic lymphohistiocytosis (HLH) like response, so close monitoring is necessary when IFN-gamma therapy is used. Depression has also been reported with IFN-gamma therapy. Patients are typically started on the same doses of IFN-gamma as are used for chronic granulomatous disease (CGD), but doses several times higher may be needed for IFN-gamma-resistant defects such as ADIFNGR1 deficiency. Dosing is adjusted based upon the patient's response to therapy and such factors as fever, inflammation, and fatigue. IFN-gamma is not usually continued as secondary prophylaxis. IFN-alpha therapy has also been used for treatment of disseminated NTM in ARIFNGR1 deficiency [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/3958.html" rel="external">"Mendelian susceptibility to mycobacterial diseases: Specific defects"</a> and  <a class="medical medical_review" href="/z/d/html/3923.html" rel="external">"Chronic granulomatous disease: Treatment and prognosis", section on 'Immunomodulatory therapy with interferon-gamma'</a>.)</p><p>Hematopoietic cell transplantation (HCT) has been successful in many forms of MSMD (ARIFNGR1, ADIFNGR1, ARSTAT1, ADSTAT1 gain of function [GOF], ARIL12RB1, and GATA2 deficiency) [<a href="#rid33">33-36</a>]. HCT for primary immunodeficiencies is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/3941.html" rel="external">"Hematopoietic cell transplantation for non-SCID inborn errors of immunity"</a>.)</p><p class="headingAnchor" id="H26818186"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Most nontuberculous mycobacterial (NTM) infections in patients with MSMD initially respond to prolonged and intensive antimycobacterial therapy (with or without cytokine therapy). However, mycobacterial infections may recur or become antibiotic resistant, and there is increased susceptibility to certain other bacterial, fungal, and viral infections. Survival in the severe genetic deficiencies often requires hematopoietic cell transplantation (HCT). Outcomes for interleukin (IL) 12 receptor beta 1 (IL-12RB1) deficiency are quite variable, with some patients dying of infection in early childhood, whereas others have minimal infection susceptibility. The overall premature mortality is approximately 30 percent for IL12RB1 deficiency in one international survey [<a href="#rid37">37</a>]. Those with partial defects, such as autosomal-dominant (AD) partial interferon (IFN) gamma receptor 1 (ADIFNGR1) deficiency, typically live well into adulthood but benefit from antimycobacterial prophylaxis.</p><p class="headingAnchor" id="H3662788577"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112831.html" rel="external">"Society guideline links: Inborn errors of immunity (previously called primary immunodeficiencies)"</a>.)</p><p class="headingAnchor" id="H26818192"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis and genetics</strong> – Host defense against intracellular pathogens including mycobacteria, <em>Salmonella</em>, certain fungi, and viruses depends upon the functional integrity of the interferon (IFN) gamma/interleukin (IL) 12 pathway. Genetic defects in the IFN-gamma/IL-12 pathway result in conditions grouped together as Mendelian susceptibility to mycobacterial diseases (MSMD), including defects in IFN-gamma receptor 1 (IFNGR1), IFN-gamma receptor 2 (IFNGR2), IL-12 receptor beta 1 (IL12RB1), IL-12 receptor beta 2 (IL12RB2), IL-12 p40, signal transducer and activator of transcription (STAT) 1, IFN regulatory factor 8 (IRF8), GATA-binding protein 2 (GATA2), nuclear factor of kappa light chain gene enhancer in B cells inhibitor alpha (NFKBIA), IFN-stimulated gene 15 (ISG15), nuclear factor kappa B essential modulator (NEMO or IKBKG), gp91phox, signal peptide peptidase-like 2A (SPPL2A), and ROR-gamma c. (See <a class="local">'Introduction'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features </strong>– Patients with MSMD typically present with severe Bacillus Calmette-Guérin (BCG; a live-attenuated strain of <em>Mycobacterium bovis</em> encountered in countries that use it as a vaccine to prevent tuberculosis) or environmental nontuberculous mycobacterial (NTM) infection  (<a class="graphic graphic_table graphicRef129034" href="/z/d/graphic/129034.html" rel="external">table 1</a>). Patients are also susceptible to infection with other intracellular pathogens, such as extraintestinal nontyphoid <em>Salmonella</em>. Clinical features of disseminated NTM infection are nonspecific and may include fever, weight loss, diarrhea, generalized lymphadenopathy, generalized cutaneous lesions, diffuse abdominal tenderness, hepatosplenomegaly, and ascites. Clinical manifestations of disseminated BCG infection are similar to those for environmental NTM infection. However, with BCG infection, the lymph nodes draining the site of inoculation may fistulize to skin and surrounding tissues. Diffuse disseminated disease with extensive liver, gut, bloodstream, meningeal, brain, and bone infection may occur. (See <a class="local">'Presentation and clinical features'</a> above and  <a class="medical medical_review" href="/z/d/html/8022.html" rel="external">"Prevention of tuberculosis: BCG immunization and nutritional supplementation", section on 'Safety and adverse effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– Firm diagnosis of a genetic disease is only established by genetic sequencing. Immunologic testing can be useful to guide gene sequencing or when variants of uncertain significance (VUS) are detected. Immunologic testing such as cell surface receptor expression and intracellular signaling (eg, lack of STAT1 phosphorylation in response to IFN-gamma or lack of STAT4 phosphorylation in response to IL-12) can be performed by flow cytometry or immunoblotting. . (See <a class="local">'General approach to diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis </strong>– The differential diagnosis in patients with disseminated NTM infections includes anti-IFN-gamma autoantibodies. The differential diagnosis for disseminated BCG includes severe T cell immunodeficiencies such as severe combined immunodeficiency (SCID), and rarely chronic granulomatous disease (CGD). (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– Aggressive treatment with antimycobacterial antibiotics is required management of patients with these disorders. Cytokine therapy with IFN-gamma is an additional treatment option for most defects. However, it has limited efficacy among patients with autosomal-recessive (AR) complete defects of IFNGR1 and IFNGR2 since unexpressed receptors cannot respond to IFN-gamma. (See <a class="local">'General approach to treatment'</a> above.)</p><p></p><p class="bulletIndent1">Hematopoietic cell transplantation (HCT) is an increasingly successful option for many defects, including IFNGR1, IFNGR2, GATA2, IKBKG (NEMO), cytochrome b-245 beta chain (CYBB; gp91phox), IL12RB1, and STAT1. Experience is limited but developing with the other defects. (See  <a class="medical medical_review" href="/z/d/html/3941.html" rel="external">"Hematopoietic cell transplantation for non-SCID inborn errors of immunity"</a>.)</p><p></p><p class="headingAnchor" id="H1003552297"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges E Richard Stiehm, MD, and Gulbu Uzel, MD, who contributed as Section Editor and author, respectively, to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wu UI, Holland SM. Host susceptibility to non-tuberculous mycobacterial infections. Lancet Infect Dis 2015; 15:968.</a></li><li><a class="nounderline abstract_t">Holland SM, Dorman SE, Kwon A, et al. Abnormal regulation of interferon-gamma, interleukin-12, and tumor necrosis factor-alpha in human interferon-gamma receptor 1 deficiency. J Infect Dis 1998; 178:1095.</a></li><li><a class="nounderline abstract_t">Newport MJ, Huxley CM, Huston S, et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996; 335:1941.</a></li><li><a class="nounderline abstract_t">Lamhamedi S, Jouanguy E, Altare F, et al. Interferon-gamma receptor deficiency: relationship between genotype, environment, and phenotype (Review). Int J Mol Med 1998; 1:415.</a></li><li><a class="nounderline abstract_t">Altare F, Jouanguy E, Lamhamedi-Cherradi S, et al. A causative relationship between mutant IFNgR1 alleles and impaired cellular response to IFNgamma in a compound heterozygous child. Am J Hum Genet 1998; 62:723.</a></li><li><a class="nounderline abstract_t">Altare F, Jouanguy E, Lamhamedi S, et al. Mendelian susceptibility to mycobacterial infection in man. Curr Opin Immunol 1998; 10:413.</a></li><li><a class="nounderline abstract_t">Roesler J, Kofink B, Wendisch J, et al. Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNgammaR1) deficiency: mutational analysis and evaluation of therapeutic options. Exp Hematol 1999; 27:1368.</a></li><li><a class="nounderline abstract_t">Dorman SE, Uzel G, Roesler J, et al. Viral infections in interferon-gamma receptor deficiency. J Pediatr 1999; 135:640.</a></li><li><a class="nounderline abstract_t">Flesch IE, Hess JH, Huang S, et al. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha. J Exp Med 1995; 181:1615.</a></li><li><a class="nounderline abstract_t">Shuai K, Schindler C, Prezioso VR, Darnell JE Jr. Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science 1992; 258:1808.</a></li><li><a class="nounderline abstract_t">Shuai K, Stark GR, Kerr IM, Darnell JE Jr. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 1993; 261:1744.</a></li><li><a class="nounderline abstract_t">Rosain J, Kong XF, Martinez-Barricarte R, et al. Mendelian susceptibility to mycobacterial disease: 2014-2018 update. Immunol Cell Biol 2019; 97:360.</a></li><li><a class="nounderline abstract_t">Holland SM, Pierce VM, Shailam R, et al. Case 28-2017. A 13-Month-Old Girl with Pneumonia and a 33-Year-Old Woman with Hip Pain. N Engl J Med 2017; 377:1077.</a></li><li><a class="nounderline abstract_t">Dorman SE, Picard C, Lammas D, et al. Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies. Lancet 2004; 364:2113.</a></li><li><a class="nounderline abstract_t">Wang LH, Yen CL, Chang TC, et al. Impact of molecular diagnosis on treating Mendelian susceptibility to mycobacterial diseases. J Microbiol Immunol Infect 2012; 45:411.</a></li><li><a class="nounderline abstract_t">Esteve-Sole A, Sánchez-Dávila SP, Deyà-Martínez A, et al. Severe BCG-osis Misdiagnosed as Multidrug-Resistant Tuberculosis in an IL-12Rβ1-Deficient Peruvian Girl. J Clin Immunol 2018; 38:712.</a></li><li><a class="nounderline abstract_t">Esteve-Solé A, Sologuren I, Martínez-Saavedra MT, et al. Laboratory evaluation of the IFN-γ circuit for the molecular diagnosis of Mendelian susceptibility to mycobacterial disease. Crit Rev Clin Lab Sci 2018; 55:184.</a></li><li><a class="nounderline abstract_t">Sarrafzadeh SA, Nourizadeh M, Mahloojirad M, et al. Molecular, Immunological, and Clinical Features of 16 Iranian Patients with Mendelian Susceptibility to Mycobacterial Disease. J Clin Immunol 2019; 39:287.</a></li><li><a class="nounderline abstract_t">Wu UI, Chuang YC, Sheng WH, et al. Use of QuantiFERON-TB Gold In-tube assay in screening for neutralizing anti-interferon-γ autoantibodies in patients with disseminated nontuberculous mycobacterial infection. Clin Microbiol Infect 2018; 24:159.</a></li><li><a class="nounderline abstract_t">Patel SY, Ding L, Brown MR, et al. Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections. J Immunol 2005; 175:4769.</a></li><li><a class="nounderline abstract_t">Browne SK, Holland SM. Immunodeficiency secondary to anticytokine autoantibodies. Curr Opin Allergy Clin Immunol 2010; 10:534.</a></li><li><a class="nounderline abstract_t">Browne SK, Burbelo PD, Chetchotisakd P, et al. Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med 2012; 367:725.</a></li><li><a class="nounderline abstract_t">Lee WI, Huang JL, Wu TS, et al. Patients with inhibitory and neutralizing auto-antibodies to interferon-γ resemble the sporadic adult-onset phenotype of Mendelian Susceptibility to Mycobacterial Disease (MSMD) lacking Bacille Calmette-Guerin (BCG)-induced diseases. Immunobiology 2013; 218:762.</a></li><li><a class="nounderline abstract_t">Chi CY, Lin CH, Ho MW, et al. Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-γ autoantibodies and disseminated nontuberculous mycobacterial infections. Medicine (Baltimore) 2016; 95:e3927.</a></li><li><a class="nounderline abstract_t">Döffinger R, Helbert MR, Barcenas-Morales G, et al. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin Infect Dis 2004; 38:e10.</a></li><li><a class="nounderline abstract_t">Höflich C, Sabat R, Rosseau S, et al. Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans. Blood 2004; 103:673.</a></li><li><a class="nounderline abstract_t">Shim HH, Cai SCS, Chan W, et al. Mycobacterium abscessus Infection During Ustekinumab Treatment in Crohn's Disease: A Case Report and Review of the Literature. J Crohns Colitis 2018; 12:1505.</a></li><li><a class="nounderline abstract_t">Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin Exp Immunol 2010; 161:1.</a></li><li><a class="nounderline abstract_t">Holland SM. Treatment of infections in the patient with Mendelian susceptibility to mycobacterial infection. Microbes Infect 2000; 2:1579.</a></li><li><a class="nounderline abstract_t">Holland SM. Immunotherapy of mycobacterial infections. Semin Respir Infect 2001; 16:47.</a></li><li><a class="nounderline abstract_t">Brown-Elliott BA, Nash KA, Wallace RJ Jr. Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria. Clin Microbiol Rev 2012; 25:545.</a></li><li><a class="nounderline abstract_t">Bax HI, Freeman AF, Ding L, et al. Interferon alpha treatment of patients with impaired interferon gamma signaling. J Clin Immunol 2013; 33:991.</a></li><li><a class="nounderline abstract_t">Patel S, Uppuluri R, Vellaichamy Swaminathan V, et al. Mendelian susceptibility to mycobacterial disease-Challenges in hematopoietic stem cell transplantation. Pediatr Blood Cancer 2020; 67:e28187.</a></li><li><a class="nounderline abstract_t">Parta M, Shah NN, Baird K, et al. Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen. Biol Blood Marrow Transplant 2018; 24:1250.</a></li><li><a class="nounderline abstract_t">Leiding JW, Okada S, Hagin D, et al. Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations. J Allergy Clin Immunol 2018; 141:704.</a></li><li><a class="nounderline abstract_t">Zerbe CS, Dimitrova D, Gea-Banacloche JJ, et al. Successful Matched Related Bone Marrow Transplantation in a Patient with Autosomal Dominant Interferon Gamma Receptor 1 Deficiency. J Clin Immunol 2020; 40:1045.</a></li><li><a class="nounderline abstract_t">de Beaucoudrey L, Samarina A, Bustamante J, et al. Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) 2010; 89:381.</a></li></ol></div><div id="topicVersionRevision">Topic 89801 Version 12.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26049967" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Host susceptibility to non-tuberculous mycobacterial infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9806040" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Abnormal regulation of interferon-gamma, interleukin-12, and tumor necrosis factor-alpha in human interferon-gamma receptor 1 deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8960473" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9852244" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Interferon-gamma receptor deficiency: relationship between genotype, environment, and phenotype (Review).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9497247" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : A causative relationship between mutant IFNgR1 alleles and impaired cellular response to IFNgamma in a compound heterozygous child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9722917" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Mendelian susceptibility to mycobacterial infection in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10480427" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Listeria monocytogenes and recurrent mycobacterial infections in a child with complete interferon-gamma-receptor (IFNgammaR1) deficiency: mutational analysis and evaluation of therapeutic options.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10547254" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Viral infections in interferon-gamma receptor deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7722441" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon gamma and tumor necrosis factor alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1281555" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7690989" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30264912" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Mendelian susceptibility to mycobacterial disease: 2014-2018 update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28902581" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Case 28-2017. A 13-Month-Old Girl with Pneumonia and a 33-Year-Old Woman with Hip Pain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15589309" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical features of dominant and recessive interferon gamma receptor 1 deficiencies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23036270" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Impact of molecular diagnosis on treating Mendelian susceptibility to mycobacterial diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30039354" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Severe BCG-osis Misdiagnosed as Multidrug-Resistant Tuberculosis in an IL-12Rβ1-Deficient Peruvian Girl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29502462" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Laboratory evaluation of the IFN-γcircuit for the molecular diagnosis of Mendelian susceptibility to mycobacterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30715640" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Molecular, Immunological, and Clinical Features of 16 Iranian Patients with Mendelian Susceptibility to Mycobacterial Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28694201" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Use of QuantiFERON-TB Gold In-tube assay in screening for neutralizing anti-interferon-γautoantibodies in patients with disseminated nontuberculous mycobacterial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16177125" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Anti-IFN-gamma autoantibodies in disseminated nontuberculous mycobacterial infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20966748" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Immunodeficiency secondary to anticytokine autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22913682" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Adult-onset immunodeficiency in Thailand and Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23083630" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Patients with inhibitory and neutralizing auto-antibodies to interferon-γresemble the sporadic adult-onset phenotype of Mendelian Susceptibility to Mycobacterial Disease (MSMD) lacking Bacille Calmette-Guerin (BCG)-induced diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27336882" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-γautoantibodies and disseminated nontuberculous mycobacterial infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14679469" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12947000" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Naturally occurring anti-IFN-gamma autoantibody and severe infections with Mycobacterium cheloneae and Burkholderia cocovenenans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30169620" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mycobacterium abscessus Infection During Ustekinumab Treatment in Crohn's Disease: A Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20491796" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : How tumour necrosis factor blockers interfere with tuberculosis immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11113377" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment of infections in the patient with Mendelian susceptibility to mycobacterial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11309712" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Immunotherapy of mycobacterial infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22763637" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23512243" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Interferon alpha treatment of patients with impaired interferon gamma signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31965686" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Mendelian susceptibility to mycobacterial disease-Challenges in hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29412158" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Allogeneic Hematopoietic Stem Cell Transplantation for GATA2 Deficiency Using a Busulfan-Based Regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28601685" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32696284" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Successful Matched Related Bone Marrow Transplantation in a Patient with Autosomal Dominant Interferon Gamma Receptor 1 Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21057261" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Revisiting human IL-12Rβ1 deficiency: a survey of 141 patients from 30 countries.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
